Description
Semaglutide is a GLP-1 receptor agonist used to improve blood sugar control in type 2 diabetes and support weight loss. It increases insulin release when blood sugar is high, reduces glucagon, slows gastric emptying, and helps increase feelings of fullness. As a result, it may reduce appetite, support fat loss, and improve metabolic health.
Semaglutide is administered by subcutaneous injection, usually once weekly. Treatment often starts with a low dose, such as 0.25 mg per week, and may be increased depending on response and tolerability. Injection sites should be rotated between the abdomen, thigh, and upper arm.
It is not suitable for everyone. People with severe hypersensitivity to Semaglutide, a personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should avoid it. Pregnant or breastfeeding women, as well as patients with severe gastrointestinal disease or diabetic retinopathy, should use it only under medical supervision.
Common side effects include nausea, vomiting, diarrhea, constipation, headache, fatigue, and dizziness. Rare but serious risks include pancreatitis, gallbladder disease, allergic reactions, and hypoglycemia, especially when combined with other glucose-lowering medications.
In sports and bodybuilding, Semaglutide is sometimes used for appetite control, weight management, and improving body composition during cutting phases. However, it should only be used responsibly and under the guidance of a healthcare professional.
Reviews
There are no reviews yet.